Agilent Technologies, Inc. Q4 FY2025 earnings call

• Strong Q4 results: $1.86 billion in revenue, 7.2% core growth, sixth consecutive quarter of core growth acceleration, above guidance. - Ignite operating system: Helped deliver over 200 basis points of sequential margin improvement, funded incremental variable pay. - Customer-focused innovation: Products like Infinity 3, Pro IQ LCMS, and Alturo BioInert column driving growth. - Unified sales and service model: Insights from service team account for 30% of sales leads with high conversion rate. - Talent acquisition: Hired key executives to drive innovation and manufacturing. - Ignite impact: Delivered over $150 million in annualized savings, helped with tariff mitigation and enterprise pricing.

In the fourth quarter, LDG (Life Sciences and Diagnostics Group) grew 11%, AMG (Applied Markets Group) grew 3%, and ACG (Agilent CrossLab Group) grew 6%. The specialty CDMO business within LDG represents nearly 20% of LDG revenue and grew more than 40% on a core basis during Q4. Currency had a favorable impact of 0.9% while M&A contributed 1.3% to the core growth.

• FY '26 core revenue guidance: 4%-6% range. - Operating margin guidance: 75 basis points expansion at midpoint. - EPS guidance: 5%-7%, with a one-time tax rate step-up reducing it by 3 percentage points. - First-quarter revenue: $1.79-$1.82 billion core growth range, EPS $1.35-$1.38.

• Macroeconomic uncertainties affecting end markets. - Tariff impacts on margins. - Challenges in the academia and government end market with continued softness due to federal spending reductions.

Q: Comment on BioVectra dynamics and CapEx?

A: BioVectra came in strong driven by GLP business, integration was outstanding; CapEx incremental $100 million for NASD capacity and consumable expansion.

Q: Talk on margins guidance and top-line impact?

A: 75 basis points margin expansion at midpoint driven by Ignite, pricing, operational efficiencies, and tariff mitigations; top-line at high end could lead to better margins.

Q: Tone from biopharma customers and budget flush?

A: Pharma grew 12%, biotech spending up, budget flush more normalized; strong momentum with Infinity 3, ProIQ LCMS, and Alturo column.

Q: China performance and pharma reshoring?

A: China down 4% in Q4, mix of market declines; pharma reshoring expected to bring orders by '26 with $1 billion addressable market opportunity for Agilent by 2030.

Q: GLP-1s business size, split, and growth outlook?

A: GLP-1s revenue ~$130 million in '25, split 60% BioVectra CDMO and 40% analytical lab; strong growth runway in '26 with India and other geographies in focus.

Q: Academic and government end market?

A: Down 10% in Q4, US federal spending reductions impactful, expected softness to continue in '26.

Q: ACG business and GC upgrade cycle?

A: ACG saw high single-digit growth ex China; GC replacement cycle starting, longer than LC, with mid-single-digit growth expected in '26.

Q: Tax rate and M&A capital deployment?

A: Tax rate increasing 2.5% due to global minimum tax, offset by operating performance; M&A disciplined, focused on fit and shareholder return, with strong BioVectra integration as example.

Q: Omnis franchise potential?

A: Omnis family has double-digit growth in instrument placements, focus on menu expansion, with strong macros supporting durable growth.

Q: Pharma biotech growth breakdown and guide?

A: Pharma biotech growth split roughly 50-50 between large and small molecule, expected to continue in '26.

Q: Lunar New Year timing impact?

A: China stimulus not in guide, Q1 guide reflects seasonality and reduced stimulus volume.

Q: R&D deployment?

A: Focused innovation with new CTO, simplified product lines, investing in software, oligos, GLP-1s, and workflow areas.